Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older at the time of signing consent
- People whose general health and ability to carry out daily activities falls within an acceptable range as rated by a standard medical scale (ECOG score of 0, 1, or 2)
- People who have been diagnosed with prostate cancer confirmed by tissue testing
- People whose surgical team has assessed them as suitable for an operation to remove the prostate (radical prostatectomy)
- People who are able to sign a written consent form and agree to the release of personal health information as approved by the relevant review board
- People who are willing to use a barrier method of contraception (such as a condom) throughout the study treatment period
Who may not be able to join:
- People who have another cancer (past or current) that the treating specialist believes could interfere with the safety or results of this study
- People who have received chemotherapy, radiation, hormone therapy, immunotherapy, or other cancer or experimental treatments within the 30 days before starting the study
- People who are currently taking certain medications that strongly or moderately affect how the body processes a specific liver enzyme (CYP3A4), unless those medications have been stopped for at least one week before joining
- People who are taking medications known to affect heart rhythm in a specific way (QT interval prolongation), or who have a history of a particular heart rhythm condition called Torsades de Pointes, or who have poorly controlled high blood pressure, low potassium or magnesium levels in the blood, slow digestion, or reduced activity of a specific enzyme involved in hormone processing (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Natalie Reizine, University of Illinois at Chicago
Phone: 312-996-1581
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate anti-tumor activity of GLY by assessing changes in prostate-specific antigen (PSA) after GLY treatment administration and prior to radical prostatectomy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.